Literature DB >> 21574128

Management of patients with low-grade gliomas - a survey among German neurosurgical departments.

M Seiz1, C F Freyschlag, S Schenkel, C Weiss, C Thomé, K Schmieder, W Stummer, J Tuettenberg.   

Abstract

BACKGROUND AND AIMS OF THE STUDY: The diagnosis and treatment of low-grade gliomas (LGG) are multimodal. Today, there is no defined standard in diagnosis and treatment. Controversies are, in general, about a "wait-and-see" strategy, diagnostic workup, surgical intervention, postoperative imaging, adjuvant treatment, and follow-up. The aim of this study is to gain an overview about management strategies of high-volume German neurosurgical departments treating these patients.
MATERIAL AND METHODS: A questionnaire including diagnostic, preoperative, perioperative, and postoperative parameters and 5 cases with magnetic resonance imaging data with questions to various treatment options in these patients was sent to all 34 German neurosurgical departments at university hospitals.
RESULTS: In total, 24 questionnaires were returned and analysed. Centres were divided into those who generally practice a "wait-and-see" strategy vs. those who do not or only in highly selected cases. Statistical analyses were performed with Fisher test and Chi (2)-test. Interestingly, 50% of all centres routinely follow a "wait-and-see" strategy.
CONCLUSION: Although the management of patients with LGG is complex and a simple questionnaire will not be able to define a standard in diagnosis and treatment, this study offers an overview on strategies at high-volume academic centres dealing with these patients. There is consensus to resect superficially located lobar and circumscribed low-grade lesions. However, the differences between centres become apparent with increasing complexity of the lesions. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21574128     DOI: 10.1055/s-0031-1275351

Source DB:  PubMed          Journal:  Cent Eur Neurosurg        ISSN: 1868-4904


  8 in total

1.  Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent locations.

Authors:  Dietmar Frey; Sarah Schilt; Valérie Strack; Anna Zdunczyk; Judith Rösler; Birat Niraula; Peter Vajkoczy; Thomas Picht
Journal:  Neuro Oncol       Date:  2014-06-12       Impact factor: 12.300

Review 2.  [Navigated transcranial magnetic stimulation for preoperative mapping of the eloquent cortex].

Authors:  T Picht
Journal:  Nervenarzt       Date:  2015-12       Impact factor: 1.214

3.  Interval brain imaging for adults with cerebral glioma.

Authors:  Gerard Thompson; Theresa A Lawrie; Ashleigh Kernohan; Michael D Jenkinson
Journal:  Cochrane Database Syst Rev       Date:  2019-12-24

4.  Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.

Authors:  S C Thust; S Hassanein; S Bisdas; J H Rees; H Hyare; J A Maynard; S Brandner; C Tur; H R Jäger; T A Yousry; L Mancini
Journal:  Eur Radiol       Date:  2018-03-23       Impact factor: 5.315

5.  Factors Affecting Surgical Decision-making-A Qualitative Study.

Authors:  Caroline Gunaratnam; Mark Bernstein
Journal:  Rambam Maimonides Med J       Date:  2018-01-29

6.  Neurosurgical patterns of care for diffuse low-grade gliomas in Sweden between 2005 and 2015.

Authors:  Louise Carstam; Anja Smits; Peter Milos; Alba Corell; Roger Henriksson; Jiri Bartek; Asgeir Store Jakola
Journal:  Neurooncol Pract       Date:  2018-07-17

7.  Low grade gliomas in eloquent locations - implications for surgical strategy, survival and long term quality of life.

Authors:  Asgeir S Jakola; Geirmund Unsgård; Kristin S Myrmel; Roar Kloster; Sverre H Torp; Sigurd Lindal; Ole Solheim
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

8.  Neurosurgical management of adult diffuse low grade gliomas in Canada: a multi-center survey.

Authors:  Osaama H Khan; Warren Mason; Paul N Kongkham; Mark Bernstein; Gelareh Zadeh
Journal:  J Neurooncol       Date:  2015-10-10       Impact factor: 4.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.